MATW vs CLYM
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MATW · Matthews International$19.33 ▼ 2.37%
CLYM · Climb Bio$10.29 ▲ 16.01%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MATW -13.9%
- CLYM +471.7%
Head to head
| Metric | MATW | CLYM |
|---|---|---|
| Price | $19.33 | $10.29 |
| Change today | ▼ 2.37% | ▲ 16.01% |
| Market cap | $603.35M | $604.42M |
| Return, 3 months | -15.9% | -24.0% |
| Return, year to date | -23.8% | +157.2% |
| Return, 1 year | -12.6% | +462.3% |
| P/E (TTM) | – | – |
| P/B | 1.2 | 2.7 |
| P/E percentile vs own 5y | 29th | 26th |
| Dividend yield | 5.25% | – |
| Revenue growth (YoY, latest qtr) | -29.6% | – |
| Net profit growth (YoY) | -254.0% | -55.8% |
| Gross margin | 36.6% | – |
| Operating margin | -3.6% | – |
| Net margin | -2.6% | – |
| Return on equity | -5.9% | -27.1% |
| Analyst target vs. price | +24.2% | +177.9% |
| Analyst buy share | 0% | 100% |
| RSI (14) | 48 | 48 |
| 30-day volatility | 32.0% | 90.4% |
| Max drawdown, 1 year | -34.9% | -50.6% |
| Trend read | Leaning bearish | Leaning bullish |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CLYM is the largest of the group by market value.
- CLYM has returned the most over the past year.
- MATW has been the calmest stock over the last 30 days.